In patients with heart failure with reduced ejection fraction, is routine overnight bilevel positive airway pressure (BiPAP) therapy indicated?

Routine Overnight BiPAP in Heart Failure with Reduced Ejection Fraction

Routine overnight BiPAP is NOT indicated for patients with heart failure with reduced ejection fraction (HFrEF) unless they have documented obstructive sleep apnea (OSA). For central sleep apnea (CSA), BiPAP and adaptive servo-ventilation are contraindicated due to increased mortality risk.

Key Recommendations by Sleep Disorder Type

Central Sleep Apnea (CSA) - DO NOT USE

• Adaptive servo-ventilation is contraindicated (Class III: Harm) in patients with NYHA class II-IV HFrEF and central sleep apnea, as it increases all-cause and cardiovascular mortality 1, 2
• BiPAP for CSA in HFrEF lacks evidence of mortality benefit and carries similar concerns as adaptive servo-ventilation
• The 2016 ESC guidelines explicitly state adaptive servo-ventilation "is not recommended in patients with HFrEF and a predominant central sleep apnoea because of an increased all-cause and cardiovascular mortality" 1

Obstructive Sleep Apnea (OSA) - Limited Indication

• CPAP (not BiPAP) is the first-line therapy for documented OSA in HFrEF patients 2
• CPAP improves sleep quality but showed no evidence of benefit on cardiovascular events in a large RCT of >2,700 patients at 3.7 years follow-up 2
• One small pilot study (n=24) suggested BiPAP may improve LVEF more than CPAP (7.9% absolute increase), but this requires larger confirmatory trials 3
• A 2026 meta-analysis found fixed-pressure CPAP improved LVEF (mean difference 4.84%), while auto-CPAP showed no significant effect 4

Clinical Algorithm

Step 1: Evaluate for sleep-disordered breathing

• Only pursue if patient has symptoms (excessive daytime sleepiness, witnessed apneas, unrefreshing sleep)
• Perform polysomnography to distinguish OSA from CSA

Step 2: If OSA is confirmed

• Initiate CPAP (not BiPAP) as first-line therapy
• Primary benefit is improved sleep quality, not mortality reduction
• Consider BiPAP only if CPAP fails or is not tolerated

Step 3: If CSA is confirmed

• Do NOT use BiPAP or adaptive servo-ventilation
• Optimize guideline-directed medical therapy (ACE-I/ARB/ARNI, beta-blockers, MRAs, SGLT2 inhibitors) 1
• CSA often improves with optimization of HF medications

Critical Pitfalls to Avoid

1. Never use adaptive servo-ventilation or BiPAP for central sleep apnea in HFrEF - this increases mortality 1, 2

2. Do not initiate positive airway pressure therapy without polysomnography - distinguishing OSA from CSA is essential, as treatments have opposite risk profiles

3. Do not expect mortality benefit from CPAP/BiPAP - even in OSA, the primary benefit is symptomatic (sleep quality), not prognostic 2

4. Prioritize evidence-based HF medications over positive airway pressure - ACE-I/ARNI, beta-blockers, MRAs, and SGLT2 inhibitors have proven mortality benefits (Class I recommendations) 1, while positive airway pressure does not

Evidence Quality and Nuances

The strongest evidence comes from the 2017 ACC/AHA/HFSA focused update 2 and 2016 ESC guidelines 1, both providing Class III (Harm) recommendations against adaptive servo-ventilation in CSA with HFrEF. The evidence for BiPAP specifically is limited to small studies 5, 3, 6 showing potential LVEF improvement in highly selected patients, but these findings have not been validated in large mortality trials. A 2019 Cochrane review found very low-quality evidence regarding mortality effects of positive airway pressure therapy overall 7.

In summary: Focus on optimizing guideline-directed medical therapy for HFrEF. Only consider CPAP (not BiPAP) if documented OSA exists and symptoms warrant treatment. Never use BiPAP or adaptive servo-ventilation for central sleep apnea in HFrEF patients.